FMP
89bio, Inc.
ETNB
NASDAQ
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
6.75 USD
0.17 (2.52%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
181.64M
121.07M
107.55M
149.9M
153.64M
152.62M
151.61M
150.61M
149.61M
148.63M
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
8.78
8.78
8.78
8.78
8.78
-
-
-
-
-
-